NCT00844922已完成2 期
Double-blind, Placebo-controlled Trial Investigating the Safety of Re-exposure to 900 mg of Org 34517, Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features), Who Participated in Trial 28130
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- Safety and tolerability measures (vital signs, AEs)
研究概览
简要总结
Patients who participated in the previous trial 28130, who were eligible, were entered into this trial. Patients who were randomized to placebo in the previous trial 28130 continued on placebo while patients who were randomized to Org 34517 (SCH 900636), regardless of dose, were titrated to 900 mg Org 34517. Patients in this trial took their study medication for 2 weeks in order to study the safety and tolerability of Org 34517.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •have attended Screening, Baseline, Visit Day 15, Day 29 and Day 43 of previous trial 28130;
- •have a CGI of Severity score of 3 or greater at Day 43 of previous trial 28130 and at Day 1 of current trial 28133, or a lower score when the investigator is of the opinion that further resolution of symptoms is warranted;
- •be on a stable dose of 'usual treatment', which must consist of an antidepressant, an antipsychotic, a mood stabilizer or any combination of these 3 drug classes.
排除标准
- •had experienced any of the following significant safety outcomes in previous trial 28130:
- •severe breakthrough bleeding;
- •diagnosis of prostatitis;
- •abnormal level of testosterone at Day 15 of previous trial 28130;
- •any adverse event deemed relevant for exclusion in trial 28133 by the investigator.
- •had an abnormal PSA test at Day -7 of previous trial 28133
- •were at significant risk of committing suicide, as indicated by a score greater than 9 on the revised ISST at Day -7 or Day 1;
- •were currently treated with carbamazepine or valproate, midazolam, or clozapine;
- •had been treated with electroconvulsive therapy (ECT) in the current episode;
- •were currently treated with more than one antidepressant, antipsychotic, or mood stabilizer;
- •had 'usual treatment' started or discontinued in the 2 weeks before Day 1;
- •had a 'usual treatment' dose change within one week prior to Day 1;
- •had any clinically unstable or uncontrollable renal, hepatic, respiratory, hematological, cardiovascular or cerebrovascular disease that would put the patient at risk of safety or bias assessment of efficacy;
- •had known hypersensitivity reactions to glucocorticoid antagonists;
- •had any clinically significant abnormal laboratory data (e.g. aspartate amino transferase (ASAT) and/or alanine amino transferase (ALAT) values > 2x normal range upper limit) or ECG results, or a clinically significant abnormal outcome at the physical examination at Day -7;
- •had a confirmed positive result on the drug screening test for any illicit drug, except cannabis, at Day -7;
- •had any untreated or uncompensated clinically significant endocrine disorder;
- •were using hormone replacement therapy at Day -7;
- •required concomitant treatment with corticosteroids (topical use was allowed);
- •women of childbearing potential without adequate contraception
- •women with a positive pregnancy test at Day -7 or 1, or are breast feeding mothers.
研究组 & 干预措施
Org 34517
Experimental
Org 34517 titrated to 900 mg daily for 2 weeks
干预措施: SCH 900636 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety and tolerability measures (vital signs, AEs)
时间窗: 4 weeks
次要结局
- 17-item Hamilton Rating Scale for Depression (HAMD) total score(4 weeks)
- proportion of BPRS 30% responders; proportion of subjects with sustained BPRS 30% response(4 weeks)
- proportion of HAMD 50% responders; proportion of subjects with sustained HAMD 50% response(4 weeks)
- clinical global impression (CGI)(4 weeks)
- PANNS total score(4 weeks)
- PANSS positive scale score, PANSS negative scale score, PANSS general psychopathology score(4 weeks)
研究者
相似试验
进行中（未招募）
2 期
LAM561 With RT and TMZ for Adults With GlioblastomaPrimary GlioblastomaGlioblastoma MultiformeNCT04250922Laminar Pharmaceuticals144
终止
3 期
A Study of PRN1008 in Patients With PemphigusPemphigusNCT03762265Principia Biopharma, a Sanofi Company131
已完成
3 期
Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar ExtractionDental PainNCT02517905Pacira Pharmaceuticals, Inc166
已完成
3 期
Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in AdultsHepatitis B VaccinesNCT03393754VBI Vaccines Inc.1,607
尚未招募
3 期
Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for GlioblastomaGlioblastomaNCT06749925University of Sao Paulo General Hospital186